Research Article
Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
Table 1
Clinical and pathologic features of men undergoing prostatectomy.
| | Parameter | Age ≤ 55 (n = 277) | Age > 55 (n = 1.923) | |
| | Follow-up (mo), median (quartiles) | 48.5 (24.0–77.3) | 50.0 (24.0–79.3) | 0.8 | | PSA (ng/mL), median (quartiles) | 5.8 (4.5–9.0) | 6.36 (4.8–9.5) | 0.038 | | Clinical stage, (%) | | | | | cT1 | 104 (37.5) | 565 (29.4) | | | cT2 | 154 (55.6) | 1098 (57.1) | 0.001 | | cT3 | 19 (6.9) | 260 (13.5) | | | Pathological stage, (%) | | | | | pT2 | 195 (70.4) | 1260 (65.5) | | | pT3a | 70 (25.3) | 519 (27.0) | 0.1 | | pT3b | 12 (4.3) | 144 (7.5) | | | Biopsy GS, (%) | | | | | 3 + 3 | 183 (66.1) | 1,125 (58.5) | | | 3 + 4 | 77 (27.8) | 597 (31.0) | | | 4 + 3 | 10 (3.6) | 75 (3.9) | 0.046 | | 8 | 5 (1.8) | 87 (4.5) | | | 9-10 | 2 (0.7) | 39 (2.0) | | | Pathological GS, (%) | | | | | 3 + 3 | 78 (28.2) | 539 (28.0) | | | 3 + 4 | 153 (55.2) | 1,011 (52.6) | | | 4 + 3 | 28 (10.1) | 183 (9.5) | 0.37 | | 8 | 11 (4.0) | 89 (4.6) | | | 9-10 | 7 (2.5) | 101 (5.3) | | | Pathological nodal status, (%) | | | | | N0 | 65 (23.5) | 619 (32.2) | | | N1 | 7 (2.5) | 62 (3.2) | 0.85 | | Surgical margins status, (%) | | | | | R0 | 214 (80.5) | 1482 (80.1) | | | R1 | 52 (19.5) | 368 (19.9) | 0.92 | | PSA relapse, (%) | 79 (28.5) | 544 (28.3) | 0.9 | | Disease progression, (%) | 1 (0.4) | 49 (2.5) | 0.026 |
|
|
PSA: prostate specific antigen, GS: Gleason score.
|
